These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 30698096)

  • 1. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
    Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
    Hong YD; Onukwugha E; Slejko JF
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Plan Enrollment and Disenrollment of Individuals With and Without Established Chronic Disease in a U.S. Commercially Insured and Medicare Advantage Population.
    Chung H; Deshpande G; Zolotarjova J; Quimbo RA; Kern DM; Cochetti PT; Willey VJ
    J Manag Care Spec Pharm; 2019 May; 25(5):612-620. PubMed ID: 31039058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
    Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization.
    Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2409-2421. PubMed ID: 31749614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
    Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a claims-based prediction model for COPD severity.
    Macaulay D; Sun SX; Sorg RA; Yan SY; De G; Wu EQ; Simonelli PF
    Respir Med; 2013 Oct; 107(10):1568-77. PubMed ID: 23806285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
    Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
    J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims.
    Mapel DW; Dalal AA; Blanchette CM; Petersen H; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2011; 6():573-81. PubMed ID: 22135490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
    Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMA study.
    Montes de Oca M; Aguirre C; Lopez Varela MV; Laucho-Contreras ME; Casas A; Surmont F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3059-3067. PubMed ID: 27994446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.